London:
Tamiflu, the anti-viral drug for swine flu, may do more harm than good to children afflicted with the H1N1 virus, a new study published on Tuesday says.
The research published in the British Medical Journal says that anti-virals Oseltamivir (Tamiflu) and Zanamivir (Relenza) are unlikely to prevent complications in children who have swine flu.
Carl Henegan, one of the authors of the report and a virus expert from the John Radcliffe Hospital in Oxford, said the British government's policy of giving Tamiflu for mild illness was an "inappropriate strategy".
Henegan and his co-author Matthew Thompson, a researcher at Oxford University, advise that children with mild symptoms should be treated just like those with other mild flu.
However, a health department spokesman said, "The BMJ review is based on seasonal flu and not swine flu ... the extent which the findings can be applied to the current pandemic is questionable.
"Whilst there is a doubt about how swine flu affects children, we believe a safety-first approach of offering anti-virals to everyone remains a sensible and responsible way forward."
While the study shows that anti-virals shorten the duration of flu in children by up to a day and a half, it also shows that they have little or no effect on asthma flare-ups,
increased ear infections or the likelihood of children needing antibiotics.
The anti-viral Tamiflu is also linked to an increased risk of vomiting.
The authors add that the study, however, reveals the effectiveness of using anti-virals to contain the spread of flu. They conclude that 13 people need to be treated to prevent one additional case; therefore anti-virals reduce transmission by 8 per cent.
During seasonal flu epidemics children are at high risk, with over 4 in 10 (40 per cent) pre-school children getting the virus and 3 in 10 (30 per cent) school age children doing so.
School age children are also the main source of spread of flu into households, say the authors.
The main strategy to control flu is vaccination, but coverage can be low and often there is not enough time to produce and distribute vaccines in response to emerging strains. Therefore current control strategies include using anti-viral medications to prevent the virus spreading as well as treating infected individuals.
Thompson and his colleagues say the last review of this strategy was carried out in 2005 and a more up to date assessment of the benefits and harms of this treatment is now required.
So they carried out a review of four trials on the treatment of flu in 1,766 children (1,243 with confirmed flu, 55 to 69 per cent with type A, the same strain as swine flu) and three trials involving the use of anti-viral to limit the spread of flu.
The authors conclude that it is difficult to know the extent to which their findings can be generalised to children in the current swine flu pandemic, but based on current evidence the effects of anti-virals on reducing the course of illness or preventing complications might be limited.
"While morbidity and mortality in the current pandemic remain low, a more conservative strategy might be considered prudent, given the limited data, side effects such as
vomiting, and the potential for developing resistant strains of influenza," they say.
The research published in the British Medical Journal says that anti-virals Oseltamivir (Tamiflu) and Zanamivir (Relenza) are unlikely to prevent complications in children who have swine flu.
Carl Henegan, one of the authors of the report and a virus expert from the John Radcliffe Hospital in Oxford, said the British government's policy of giving Tamiflu for mild illness was an "inappropriate strategy".
Henegan and his co-author Matthew Thompson, a researcher at Oxford University, advise that children with mild symptoms should be treated just like those with other mild flu.
However, a health department spokesman said, "The BMJ review is based on seasonal flu and not swine flu ... the extent which the findings can be applied to the current pandemic is questionable.
"Whilst there is a doubt about how swine flu affects children, we believe a safety-first approach of offering anti-virals to everyone remains a sensible and responsible way forward."
While the study shows that anti-virals shorten the duration of flu in children by up to a day and a half, it also shows that they have little or no effect on asthma flare-ups,
increased ear infections or the likelihood of children needing antibiotics.
The anti-viral Tamiflu is also linked to an increased risk of vomiting.
The authors add that the study, however, reveals the effectiveness of using anti-virals to contain the spread of flu. They conclude that 13 people need to be treated to prevent one additional case; therefore anti-virals reduce transmission by 8 per cent.
During seasonal flu epidemics children are at high risk, with over 4 in 10 (40 per cent) pre-school children getting the virus and 3 in 10 (30 per cent) school age children doing so.
School age children are also the main source of spread of flu into households, say the authors.
The main strategy to control flu is vaccination, but coverage can be low and often there is not enough time to produce and distribute vaccines in response to emerging strains. Therefore current control strategies include using anti-viral medications to prevent the virus spreading as well as treating infected individuals.
Thompson and his colleagues say the last review of this strategy was carried out in 2005 and a more up to date assessment of the benefits and harms of this treatment is now required.
So they carried out a review of four trials on the treatment of flu in 1,766 children (1,243 with confirmed flu, 55 to 69 per cent with type A, the same strain as swine flu) and three trials involving the use of anti-viral to limit the spread of flu.
The authors conclude that it is difficult to know the extent to which their findings can be generalised to children in the current swine flu pandemic, but based on current evidence the effects of anti-virals on reducing the course of illness or preventing complications might be limited.
"While morbidity and mortality in the current pandemic remain low, a more conservative strategy might be considered prudent, given the limited data, side effects such as
vomiting, and the potential for developing resistant strains of influenza," they say.
